Clarametyx Biosciences Announces $33 Million Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections

Newly established relationship with Cystic Fibrosis Foundation enables clinical studies targeting cystic fibrosis-associated infections